1Department of Urology, Yeungnam Hospital of Medicine, Daegu, Korea
2Department of Physical Medicine and Rehabilitation, Yeungnam University College of Medicine, Daegu, Korea
3Department of Urology, Yeungnam University College of Medicine, Daegu, Korea
Copyright © 2021 Yeungnam University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PFME with biofeedback group (n=41, 49.4%) | Conventional Kegel exercise group (n=42, 50.6%) | Total (n=83) | p-value | |
---|---|---|---|---|
Age (yr) | 68.4±5.98 | 67.7±4.90 | 68.1±5.44 | 0.561 |
<65 | 12 (29.3) | 13 (31.0) | 25 | 0.952 |
65−70 | 16 (39.0) | 17 (40.5) | 33 | |
>70 | 13 (31.7) | 12 (28.5) | 25 | |
Diabetes mellitus | ||||
No | 37 (90.2) | 34 (81.0) | 71 | 0.229 |
Yes | 4 (9.8) | 8 (19.0) | 12 | |
Coronary heart disease | ||||
No | 36 (87.8) | 40 (95.2) | 76 | 0.223 |
Yes | 5 (12.2) | 2 (4.8) | 7 | |
Gleason score | ||||
<8 | 23 (56.1) | 31 (73.8) | 54 | 0.091 |
≥8 | 18 (43.9) | 11 (26.2) | 29 | |
Prostate volume (gm) | 33.8±15.2 | 36.2±13.8 | 35.0±14.5 | 0.448 |
<40 | 31 (75.6) | 27 (64.3) | 58 | 0.261 |
≥40 | 10 (24.4) | 15 (35.7) | 25 | |
Initial PSA (ng/dL) | 45.4±78.7 | 16.8±20.5 | 30.9±58.6 | 0.025 |
<20 | 29 (70.7) | 34 (81.0) | 63 | 0.276 |
≥20 | 12 (29.3) | 8 (19.0) | 20 | |
Pathological T stage | ||||
≤pT2 | 19 (46.3) | 24 (57.1) | 43 | 0.325 |
≥pT3 | 22 (53.7) | 18 (42.9) | 40 | |
Nerve-sparing procedure | ||||
Non-NS | 33 (80.5) | 35 (83.3) | 68 | 0.736 |
NS RARP | 8 (19.5) | 7 (16.7) | 15 | |
Adjuvant radiation | ||||
No RT | 39 (95.1) | 40 (95.2) | 79 | 0.98 |
Adjuvant RT | 2 (4.9) | 2 (4.8) | 4 |
PFME with biofeedback group (n=41, 49.4%) | Conventional Kegel exercise group (n=42, 50.6%) | Total (n=83) | p-value | |
---|---|---|---|---|
Pad period (day) | 32.4±30.3 | 95.3±98.5 | 64.2±79.4 | <0.001 |
Continence regain within 1 wk | ||||
Zero pad | 9 (22.0) | 6 (14.3) | 15 (18.1) | 0.364 |
Incontinence | 32 (78.0) | 36 (85.7) | 68 (81.9) | |
Continence regain within 1 mo | ||||
Zero pad | 25 (61.0) | 16 (38.1) | 41 (49.4) | 0.037 |
Incontinence | 16 (39.0) | 26 (61.9) | 42 (50.6) | |
Continence regain within 3 mo | ||||
Zero pad | 41 (100) | 23 (54.8) | 64 (77.1) | <0.001 |
Incontinence | 0 | 19 (45.2) | 19 (22.9) | |
Continence regain within 6 mo | ||||
Zero pad | 41 (100) | 37 (88.1) | 78 (94.0) | 0.023 |
Incontinence | 0 | 5 (11.9) | 5 (6.0) |
Variable | Continence within 3 mo |
Total (n=83) | p-value | |
---|---|---|---|---|
Continence (n=64, 77.1%) | Incontinence (n=19, 22.9%) | |||
Age (yr) | 68.0±5.45 | 68.3±5.53 | 68.1±5.44 | 0.854 |
<65 | 20 (31.3) | 5 (26.4) | 25 | 0.763 |
65−70 | 26 (40.6) | 7 (36.8) | 33 | |
>70 | 18 (28.1) | 7 (36.8) | 25 | |
Diabetes mellitus | ||||
No | 55 (85.9) | 16 (84.2) | 71 | 0.851 |
Yes | 9 (14.1) | 3 (15.8) | 12 | |
Coronary heart disease | ||||
No | 58 (90.6) | 18 (94.7) | 76 | 0.571 |
Yes | 6 (9.4) | 1 (5.3) | 7 | |
Gleason score | ||||
<8 | 41 (64.1) | 13 (68.4) | 54 | 0.726 |
≥8 | 23 (35.9) | 6 (31.6) | 29 | |
Prostate volume (gm) | 34.0±15.1 | 38.5±12.3 | 35.0±14.5 | 0.234 |
<40 | 47 (73.4) | 11 (57.9) | 58 | 0.195 |
≥40 | 17 (26.6) | 8 (42.1) | 25 | |
Initial PSA (ng/dL) | 33.2±65.1 | 23.5±27.9 | 30.9±58.6 | 0.529 |
<20 | 50 (78.1) | 13 (68.4) | 63 | 0.385 |
≥20 | 14 (21.9) | 6 (31.6) | 20 | |
Pathological T stage | ||||
≤pT2 | 30 (46.9) | 13 (68.4) | 43 | 0.099 |
≥pT3 | 34 (53.1) | 6 (31.6) | 40 | |
Nerve-sparing procedure | ||||
Non-NS | 54 (84.4) | 14 (73.7) | 68 | 0.288 |
NS RARP | 10 (15.6) | 5 (26.3) | 15 | |
Adjuvant radiation | ||||
No RT | 61 (95.3) | 18 (94.7) | 79 | 0.918 |
Adjuvant RT | 3 (4.7) | 1 (5.3) | 4 | |
PFME with biofeedback | ||||
No | 23 (35.9) | 19 (100.0) | 42 | <0.001 |
Yes | 41 (64.1) | 0 (0.0) | 41 |
Variable (reference value) | p-value | OR (95% CI) |
---|---|---|
Age (<65 yr) | 0.149 | 1.535 (0.857−2.749) |
Diabetes mellitus | 0.165 | 1.753 (0.793−3.873) |
Coronary heart disease (no) | 0.952 | 0.968 (0.338−2.773) |
Gleason score (<8) | 0.040 | 2.167 (1.035−4.539) |
Prostate volume (<40 gm) | 0.342 | 0.743 (0.403−1.371) |
Initial PSA (<20 ng/dL) | 0.018 | 2.909 (1.197−7.072) |
Pathological T stage (≤pT2) | 0.917 | 0.965 (0.497−1.876) |
Nerve-sparing (yes) | 0.573 | 0.760 (0.292−1.977) |
Adjuvant radiation (no) | 0.735 | 0.798 (0.217−2.941) |
PFME (yes) | <0.001 | 3.731 (2.081−6.690) |
Values presented as mean±standard deviation or number (%). PFME, pelvic floor muscle exercise; PSA, prostate specific antigen; NS, nerve-sparing; RARP, robot-assisted radical prostatectomy; RT, radiation therapy.
Values presented as mean±standard deviation or number (%). PFME, pelvic floor muscle exercise.
Values presented as mean±standard deviation or number (%). PSA, prostate specific antigen; NS, nerve-sparing; RARP, robot-assisted radical prostatectomy; RT, radiation therapy; PFME, pelvic floor muscle exercise.
OR, odds ratio; CI, confidence interval; PSA, prostate specific antigen; PFME, pelvic floor muscle exercise.